HC Wainwright Estimates Disc Medicine Q1 Earnings

Disc Medicine, Inc. (NASDAQ:IRON) – Research analysts at HC Wainwright issued their Q1 2027 EPS estimates for shares of Disc Medicine in a report issued on Friday, November 6th. HC Wainwright analyst D. Tsao expects that the company will post earnings per share of ($1.53) for the quarter. HC Wainwright currently has a “Buy” rating and a $127.00 target price on the stock. The consensus estimate for Disc Medicine’s current full-year earnings is ($6.54) per share.

A number of other brokerages have also recently weighed in on IRON. Truist Financial raised their price objective on shares of Disc Medicine from $83.00 to $115.00 and gave the stock a “buy” rating in a research note on Monday, October 19th. Wells Fargo & Company increased their target price on Disc Medicine from $86.00 to $124.00 and gave the company an “overweight” rating in a report on Tuesday, October 20th. Jefferies Financial Group reissued a “buy” rating and set a $149.00 price target on shares of Disc Medicine in a research report on Wednesday, October 21st. BMO Capital Markets boosted their price target on Disc Medicine from $100.00 to $120.00 and gave the stock an “outperform” rating in a report on Monday, October 19th. Finally, Wedbush boosted their price target on Disc Medicine from $100.00 to $110.00 and gave the stock an “outperform” rating in a report on Monday, October 19th. Twelve equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $124.18.

Disc Medicine Trading Up 3.0%

NASDAQ:IRON opened at $81.26 on Monday. Disc Medicine has a 52-week low of $40.00 and a 52-week high of $99.50. The company has a quick ratio of 24.14, a current ratio of 24.14 and a debt-to-equity ratio of 0.09. The stock has a fifty day simple moving average of $71.23 and a 200-day simple moving average of $70.97. The company has a market capitalization of $3.12 billion, a PE ratio of -12.82 and a beta of 0.96.

Disc Medicine (NASDAQ:IRON) last announced its quarterly earnings results on Thursday, November 5th. The company reported ($1.53) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.63) by $0.10.

Hedge Funds Weigh In On Disc Medicine

Several large investors have recently added to or reduced their stakes in IRON. BlackRock Inc. purchased a new stake in Disc Medicine in the 2nd quarter valued at about $180,502,000. Wellington Management Group LLP lifted its holdings in shares of Disc Medicine by 0.3% during the 2nd quarter. Wellington Management Group LLP now owns 1,741,351 shares of the company’s stock worth $127,362,000 after acquiring an additional 5,975 shares during the period. Assenagon Asset Management S.A. boosted its position in shares of Disc Medicine by 191.4% in the third quarter. Assenagon Asset Management S.A. now owns 1,119,458 shares of the company’s stock worth $73,280,000 after acquiring an additional 735,300 shares during the last quarter. Opaleye Management Inc. boosted its position in shares of Disc Medicine by 103.1% in the second quarter. Opaleye Management Inc. now owns 855,000 shares of the company’s stock worth $62,535,000 after acquiring an additional 434,000 shares during the last quarter. Finally, Aberdeen Group plc grew its holdings in Disc Medicine by 36.4% in the third quarter. Aberdeen Group plc now owns 597,841 shares of the company’s stock valued at $39,135,000 after purchasing an additional 159,667 shares during the period. 83.70% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Disc Medicine news, Director Kevin Bitterman sold 25,519 shares of Disc Medicine stock in a transaction that occurred on Wednesday, October 21st. The shares were sold at an average price of $80.23, for a total value of $2,047,389.37. Following the completion of the sale, the director directly owned 12,991 shares of the company’s stock, valued at approximately $1,042,267.93. The trade was a 66.27% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO John Quisel sold 33,000 shares of the business’s stock in a transaction on Monday, August 17th. The shares were sold at an average price of $79.15, for a total value of $2,611,950.00. Following the completion of the transaction, the chief executive officer owned 226,064 shares of the company’s stock, valued at $17,892,965.60. This trade represents a 12.74% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 168,046 shares of company stock worth $13,191,034. 3.76% of the stock is owned by insiders.

Disc Medicine Company Profile

Disc Medicine, Inc is a clinical-stage biopharmaceutical company developing treatments for serious hematologic diseases. Its research focuses on disorders involving heme production and iron regulation, biological processes that affect red blood cell function.

The company’s development pipeline includes bitopertin, an investigational treatment for erythropoietic protoporphyria and X-linked protoporphyria, and DISC-0974, an investigational therapy being studied for anemia associated with myelofibrosis and chronic kidney disease.